9-(3-(N,N-二甲基氨基)丙基)咔唑 | 20811-26-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 9-(3-(N,N-二甲基氨基)丙基)咔唑
• 英文名称: 9-<3-(Dimethylamino)propyl>carbazole
• 英文别名: 3-(9H-carbazol-9-yl)-N,N-dimethylpropan-1-amine；3-carbazol-9-yl-N,N-dimethylpropan-1-amine；[3-(9H-carbazol-9-yl)propyl]dimethylamine；9-(3-dimethylaminopropyl)-9H-carbazole；9-(3-dimethylamino-propyl)-carbazole；9-(3-Dimethylamino-propyl)-carbazol；Carbazole, 9-(3-(dimethylamino)propyl)-
• CAS: 20811-26-1
• 化学式: C₁₇H₂₀N₂
• 分子量: 252.359
• InChiKey: YSZTZAYSHQJVQU-UHFFFAOYSA-N

物化性质

• 熔点：
  175-177 °C
• 沸点：
  152-155 °C(Press: 0.3 Torr)
• 密度：
  1.04±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  8.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  9-(3-(N,N-二甲基氨基)丙基)咔唑 在 三乙胺 作用下， 以 四氢呋喃 、 1,2-二氯乙烷 为溶剂， 反应 52.0h， 生成 N-(3-carbazol-9-ylpropyl)-2-(4-methoxyphenyl)-N-methylacetamide
  参考文献：
  名称：

  NB 06: From a simple lysosomotropic aSMase inhibitor to tools for elucidating the role of lysosomes in signaling apoptosis and LPS-induced inflammation

  摘要：

  Ceramide generation is involved in signal transduction of cellular stress response, in particular during stress-induced apoptosis in response to stimuli such as minimally modified Low-density lipoproteins, TNFalpha and exogenous C-6-ceramide. In this paper we describe 48 diverse synthetic products and evaluate their lysosomotropic and acid sphingomyelinase inhibiting activities in macrophages. A stimuli induced increase of C-16-ceramide in macrophages can be almost completely suppressed by representative compound NB 06 providing an effective protection of macrophages against apoptosis. Compounds like NB 06 thus offer highly interesting fields of application besides prevention of apoptosis of macrophages in atherosclerotic plaques in vessel walls. Most importantly, they can be used for blocking pH dependent lysosomal processes and enzymes in general as well as for analyzing lysosomal dependent cellular signaling. Modulation of gene expression of several prominent inflammatory messengers IL1B, IL6, IL23A, CCL4 and CCL20 further indicate potentially beneficial effects in the field of (systemic) infections involving bacterial endotoxins like LPS or infections with influenza A virus. (C) 2017 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2017.09.021
• 作为产物：
  描述：

  4,4'-dimethoxy-2-nitrobiphenyl 在 联苯 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 9-(3-(N,N-二甲基氨基)丙基)咔唑
  参考文献：
  名称：

  Carbazole compounds and therapeutic uses of the compounds

  摘要：

  通用结构式（I）和（II）的化合物以及这些化合物及其盐和水合物的用途作为治疗剂被披露。可治疗的疾病和症状包括癌症、炎症性疾病和症状，以及免疫功能缺陷疾病。 (I), (II).

  公开号：

  US09108916B2

文献信息

• A Route to Regioselectively Functionalized Carbazoles, Dibenzofurans, and Dibenzothiophenes through Anionic Cyclization of Benzyne-Tethered Aryllithiums
  作者：Roberto Sanz、Yolanda Fernández、M Pilar Castroviejo、Antonio Pérez、Francisco J. Fañanás

  DOI：10.1021/jo060911c

  日期：2006.8.1

  available products, with 3.3 equiv of t-BuLi and further reaction with selected electrophiles gives rise to functionalized carbazole, dibenzofuran, and dibenzothiophene derivatives in a direct and regioselective manner. The process involves an anionic cyclization on a benzyne-tethered aryllithium intermediate.

  用3.3当量的t- BuLi处理易于从市售产品中制备的2-氟苯基2-碘苯胺，醚和硫醚，然后与选定的亲电试剂进一步反应，可以直接和直接生成官能化的咔唑，二苯并呋喃和二苯并噻吩衍生物。区域选择性方式。该方法涉及在苯炔系留的芳基锂中间体上进行阴离子环化。
• Carbazole inhibitors of histamine receptors for the treatment of disease
  申请人：Kalypsys, Inc

  公开号：US08080566B1

  公开（公告）日：2011-12-20

  The present invention relates to carbazole compounds, pharmaceutical compositions comprising them, and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.

  本发明涉及咔唑化合物，包括它们的药物组合物，以及可能作为H1R和/或H4R的抑制剂用于治疗或预防炎症性、自身免疫性、过敏性和眼部疾病的方法。
• [EN] CALCIUM RECEPTOR MODULATING AGENTS<br/>[FR] AGENTS MODULATEURS DE RECEPTEUR DE CALCIUM
  申请人：AMGEN INC

  公开号：WO2003099814A1

  公开（公告）日：2003-12-04

  The compounds of the invention are represented by the following general structure (I) or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or inhibit PTH secretion, including methods for reducing or inhibiting PTH secretion and methods for treatment or prophylaxis of diseases associated with bone disorders, such as osteoporosis, or associated with excessive secretion of PTH, such as hyperparathyroidism. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  本发明的化合物由以下一般结构（I）或其药用可接受的盐所代表，以及含有它们的组合物，其中变量在此处定义，并且它们用于减少或抑制PTH分泌，包括用于减少或抑制PTH分泌的方法以及用于治疗或预防与骨疾病相关的疾病的方法，如骨质疏松症，或与PTH过度分泌相关的疾病，如甲状旁腺功能亢进症。本发明还涉及制备此类化合物的过程以及在这些过程中有用的中间体。
• [EN] CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS<br/>[FR] COMPOSÉS CARBAZOLE ET UTILISATIONS THÉRAPEUTIQUES DESDITS COMPOSÉS
  申请人：CLEVELAND BIOLABS INC

  公开号：WO2010042445A1

  公开（公告）日：2010-04-15

  Compounds of the general structural formula (I) and (II) and use of the compounds and salts and hydrates thereof, as therapeutic agents are disclosed. Treatable diseases and conditions include cancers, inflammatory diseases and conditions, and immunodeficiency diseases. (I), (II).

  本发明揭示了一般结构式(I)和(II)的化合物及其盐和水合物的使用作为治疗剂。可治疗的疾病和病况包括癌症、炎症性疾病和病况，以及免疫缺陷病。 (I), (II)。
• Calcium receptor modulating agents
  申请人：——

  公开号：US20040077619A1

  公开（公告）日：2004-04-22

  The compounds of the invention are represented by the following general structure 1 or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or inhibit PTH secretion, including methods for reducing or inhibiting PTH secretion and methods for treatment or prophylaxis of diseases associated with bone disorders, such as osteoporosis, or associated with excessive secretion of PTH, such as hyperparathyroidism. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  本发明的化合物由以下一般结构1或其药学上可接受的盐所代表，以及含有它们的组成物，其中变量在此被定义，并且它们的用途是减少或抑制甲状旁腺激素（PTH）的分泌，包括减少或抑制PTH分泌的方法以及治疗或预防与骨疾病相关的疾病的方法，例如骨质疏松症，或与PTH过度分泌相关的疾病，例如甲状旁腺功能亢进症。本发明还涉及制备这种化合物的过程以及在这种过程中有用的中间体。